Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

With reference to Gubra's A/S (CPSE:GUBRA) announcement on March 28, 2025 regarding the satisfaction of the regulatory condition for a license agreement to develop GUB014295, a potential ...

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Data Expected in April 2025 from Part 2 of Phase 1 Trial of DA-1726 ...

The candidate is a long-acting amylin analog for the treatment of obesity, and I am delighted to see that AbbVie did not just in-license another incretin therapy (GLP-1 or GLP-1/GIP agonist ...

In what it says is the biggest obesity deal to date, Zealand Pharma A/S has signed up Roche AG to a potential $5.3 billion global collaboration and license agreement to develop petrelintide, an amylin ...

Petrelintide is an amylin analog that Zealand claims has best-in-class potential for the treatment of obesity, and it is both a potential alternative to GLP-1 agonists like Novo Nordisk’s ...

GUB014295 is currently in a Phase 1 clinical trial. A potential long-acting amylin analog, GUB014295 is an agonist that specifically activates amylin and calcitonin receptors. Amylin, a satiety ...

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to co-develop a weight-loss treatment.

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, ...

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs ...